Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...
Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...
The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...
Program honors Eli Lilly chemist and preservationist Stan Cox INDIANAPOLIS (February 12, 2025) — Applications are open for ...
Cynthia Cassell, a former U.S. Fulbright student scholar, says the Bidirectional Training Initiative will improve Lima ...
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an ...
Maybe I'm an arrogant Luddite, but I still think I can write a better column about Indiana than artificial intelligence can.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback